Reimbursed Care Access in Macao

Currently classified as a strictly controlled substance under Macau’s anti‑drug law framework (Lei n.º 17/2009 and subsequent amendments), with no authorized medical use or reimbursement outside of approved clinical research. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use or reimbursement outside of approved clinical research. The Law on the Prohibition of illicit production, trafficking and consumption of narcotics and psychotropic substances (Lei n.º 17/2009 and subsequent updates) governs scheduling and penalties. #

Esketamine (the pharmaceutical product marketed e.g., Spravato) has no publicly available record of a Macau‑wide marketing approval or funded, reimbursed program in Macau’s official Boletim Oficial updates; Macau’s drug control framework governs psychotropic and controlled substances, and newer centrally regulated psychiatric products typically require local registration/authorization before routine use or reimbursement. Ketamine and related substances are explicitly scheduled in Macau’s tables (ketamine appears in the official drug schedule annexes), which indicates regulatory control and hospital/medical‑setting use is governed by health authorities rather than an open outpatient reimbursed program. Therefore, esketamine would require local regulatory approval and a defined reimbursement pathway to be covered; no such pathway is evident in the Macau Boletim Oficial or government health releases as of the cited law updates. # #

Ketamine is explicitly listed in Macau’s controlled substances tables (Table II‑C in the Boletim Oficial annexes), indicating it is a controlled psychotropic/anaesthetic substance subject to regulatory control; its principal lawful use in Macau is medical (e.g., anaesthesia) under the supervision/authorization of health services rather than as a reimbursed psychiatric psychedelic program. Public documentation (Boletim Oficial schedules and Macau government drug‑control communications) treats ketamine as a regulated substance with penal provisions for illicit possession/trafficking, while medical/clinical uses remain within hospital/health‑bureau oversight and are not described as having a dedicated reimbursed psychiatric indication (e.g., for depression infusion clinics) in the public record. Clinically‑oriented off‑label psychiatric ketamine (infusions) would be delivered under medical practice rules and billed privately unless/until a formal public reimbursement policy is established. # #

Currently classified as a strictly controlled substance under Macau’s drug scheduling and anti‑trafficking law, with no authorized medical use or reimbursement outside of approved clinical research. Macau’s law and the Boletim Oficial amendments add and maintain lists of controlled psychotropic substances; DMT would be subject to those controls and penal provisions. #

Currently classified as a strictly controlled substance under Macau’s anti‑drug legal regime, with no authorized medical use or reimbursement outside of approved clinical research. Substances of this chemical class are covered by the tables annexed to Lei n.º 17/2009 and its amendments. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use or reimbursement outside of approved clinical research. The Macau anti‑drug statutes and schedules incorporate psychotropic and non‑medical psychoactive substances under strict control; there is no public record of an approved medical/rehabilitation program using ibogaine in Macau. #

Currently classified as a strictly controlled substance under Macau’s drug scheduling laws when it contains scheduled tryptamines (e.g., DMT) and therefore has no authorized medical use or reimbursement outside of approved clinical research. Preparations containing scheduled substances fall under the prohibition and penal provisions of Lei n.º 17/2009 and its amendments. #

Currently classified as a strictly controlled substance under Macau’s anti‑drug law, with no authorized medical use or reimbursement outside of approved clinical research. Mescaline and other phenethylamine psychedelics fall within the statute’s controlled substance framework and associated penal provisions. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use or reimbursement outside of approved clinical research. Macau’s law and its regularly updated annexed tables explicitly expand control lists to include new synthetic psychoactive compounds; 2C‑series phenethylamines are treated under that model. #